CJC-1295 vs Sermorelin
The Two Main GHRH Analogues — Which Is Right for Your Protocol?
Sermorelin is the natural GHRH fragment with the most human safety data of any GHRH compound. CJC-1295 is a synthetic modification that is more potent and longer-acting. Both stimulate the same pituitary GHRH receptor — but their availability, safety record, and typical use context differ substantially.
Head-to-Head Comparison
| Feature | CJC-1295 | Sermorelin |
|---|---|---|
| Structure | Synthetic GHRH(1-29) analogue with 4 AA substitutions | Natural GHRH(1-29) fragment — no modifications |
| Half-life | ~30 min (No DAC) / ~8 days (DAC) | ~10–12 minutes |
| Potency (per dose) | Higher — protease-resistant modifications | Lower — rapidly degraded |
| Human Safety Data | Limited formal human trials | Extensive — formerly FDA-approved |
| Availability | Research compound; compounding pharmacies (limited) | Compounding pharmacies widely; some clinics |
| Injection Frequency | 1–3x daily (No DAC) / 1–2x weekly (DAC) | Daily (typically nightly) |
| IGF-1 Effect | Stronger elevation — especially DAC form | Modest, dose-dependent elevation |
| Physician-Supervised Use | Less common in formal clinical settings | Standard at longevity clinics and HRT programs |
| Cost | Variable; research sources cheaper | Pharmacy-compounded; prescription required |
Understanding the Key Differences
CJC-1295: More Potent, Less Data
CJC-1295's four amino acid substitutions (at positions 2, 8, 15, and 27 of the GHRH(1-29) sequence) protect it from the key serum proteases that rapidly degrade natural GHRH and sermorelin. This enzymatic resistance gives it a 2–3x longer half-life than sermorelin, producing a more sustained GHRH receptor stimulation per injection and measurably stronger IGF-1 elevation per equivalent dose.
The trade-off is a near-complete absence of formal human safety trials. CJC-1295 has not undergone the same regulatory scrutiny as sermorelin. For self-directed research compound users, this is a known and accepted trade-off. For physician-supervised patients, it makes CJC-1295 a harder compound to prescribe within standard formularies.
Sermorelin: The Established Option
Sermorelin is the natural GHRH(1-29) fragment — exactly the same biologically active portion of endogenous GHRH, with no synthetic modifications. It was FDA-approved as Geref (somatrelin) for pediatric growth hormone deficiency and used clinically from the 1990s through the early 2000s, accumulating a substantial human safety record before being discontinued for commercial (not safety) reasons.
Its primary limitation is half-life — approximately 10–12 minutes in circulation — which means it must be injected nightly for consistent pituitary stimulation. Because it is rapidly degraded, it relies on the timing of endogenous GHRH-sensitive pituitary windows (primarily the overnight GH pulse) rather than maintaining a sustained signal throughout the day.
Who Should Choose Each Compound?
Choose CJC-1295 If...
- →You are a research compound user prioritizing potency and IGF-1 elevation
- →You are building a 2–3x daily GHRP stack and need a GHRH analogue at each dose window
- →You want a once or twice weekly option via the DAC form for maximum convenience
- →You have prior experience with GH peptides and are monitoring IGF-1 labs
Choose Sermorelin If...
- →You are in a physician-supervised longevity or HRT program where sermorelin is formulary
- →You prefer the compound with the deepest human safety record and prior FDA approval history
- →You are older and your physician prefers the most-studied GHRH analogue
- →You are beginning GH peptide use and want the most conservative starting point
FAQ
What is the difference between CJC-1295 and sermorelin?
Sermorelin is the natural GHRH(1-29) fragment with the most extensive human safety record of any GHRH analogue — formerly FDA-approved for pediatric GHD. It has a half-life of ~10–12 minutes and is injected nightly. CJC-1295 is a synthetic GHRH analogue with four amino acid substitutions for protease resistance, giving it a longer half-life (~30 min No DAC, ~8 days DAC) and greater potency per dose. CJC-1295 has limited formal human trial data compared to sermorelin.
Is sermorelin safer than CJC-1295?
Based on available data, yes — sermorelin has a substantially larger human safety database accumulated through FDA-approved clinical use. CJC-1295 lacks formal human clinical trials in large populations. For physician-supervised programs, sermorelin is the more defensible choice. For informed research compound users, both are widely used, but the relative absence of human CJC-1295 safety data is worth acknowledging.
Can CJC-1295 and sermorelin be stacked together?
No recognized protocol stacks CJC-1295 and sermorelin together — both target the same GHRH receptor and stacking them would not produce synergy. The effective stacking strategy is to pair one GHRH analogue (either CJC-1295 or sermorelin) with a GHRP (ipamorelin, GHRP-2, or GHRP-6), because GHRH-R and GHSR-1a are genuinely complementary receptors with synergistic intracellular pathways.
Track CJC-1295 or Sermorelin — Free
Shotlee tracks your GHRH analogue injections, timing, dose, and response data so you can actually see what your GH protocol is doing over time.
Get Shotlee Free